Valerion to Present Initial Clinical Data with VAL-1221 in Pompe Disease
Tuesday, February 06, 2018
Valerion Therapeutics, a clinical-stage biotechnology company that specializes in the development of therapies for orphan genetic diseases, today announced that a poster highlighting initial results from the first cohort of its ongoing Phase 1/2 clinical study with VAL-1221 in patients with late-onset Pompe disease will be presented at the 14th Annual WORLDSymposium™ 2018, being held February 5-9, 2018 in San Diego, CA.
"We are delighted to present these initial clinical findings from the first dosing cohort of our ongoing clinical study with VAL-1221 and look forward to providing further updates as the trial progresses into higher dosing cohorts," said Deborah Ramsdell, CEO of Valerion. "By targeting and clearing both lysosomal and extra-lysosomal glycogen in the cytoplasm, VAL-1221 has the potential to provide new therapeutic options to patients with late-onset Pompe disease."
Poster Presentation:
Treatment of Pompe Disease with VAL-1221 (Poster #323)
Wednesday, February 7, 2018 4:30 – 6:30p.m. PT
Valerion Therapeutics, Duke University Medical Center, University College London
